## **KISUNLA™** Referral Form





Fax Completed Form To:

Phone:

Tux completed form to.						
		PATIE	NT INFORMATION			
Patient Name:		Γ			Date of Birth:	
Referral Date: Updated Order Order Renewal						
Address: City/State/Zip:						
Home Phone:		Cell Phone:			Work Phone:	
Secondary Contact:		Height:	Weight:		☐ Male ☐ Female	
Allergies:						
Current Medications:						
Other Medical Conditions or Additional Comments:						
Medical History Related to IV Insertion (e.g. lymph nodes or mastectomy):						
DIAGNOSIS						
Patient Diagnosis & ICD-10: G30.0 - Alzheimer's disease with early onset G30.1 - Alzheimer's disease with late onset G30.8 - Other Alzheimer's disease						
Prescriber must indicate the following requirements have been met to confirm diagnosis & that Patient has evidence of AD neuropathology & has been assessed for baseline ARIA risk via MRI:						
☐ Amyloid pathology confirmed via: ☐ Amyloid PET Scan - <b>OR</b> - ☐ CSF Analysis - <b>OR</b> - ☐ Blood plasma Result: ☐ Amyloid positive ☐ Amyloid negative ( <i>Kisunla</i> ™ <i>is not a treatment option for this Patient, if checked</i> )					Date:	
☐ Recent MRI obtained prior to initiating Kisunla™ (including FLAIR and T2/GRE or SWI) to assess ARIA risk☐ Prescriber has verified that this Patient does not have evidence of prior ARIA-H					Date:	
☐ Completion of cognitive assessment type: ☐ MMSE ☐ MoCA ☐ CDR ☐ Other:  Score:					Date:	
☐ Completion of functional assessment type: ☐ FAQ ☐ FAST ☐ Other:					Date:	
☐ Results for ApoE Testing				Date:		
☐ Completion of CMS approved CED registry (only required for Patients with Medicare)  ClinicalTrials.gov Registry Number: NCT Submission Number (if applicable):					CED Submission Date:	
Note: MRIs must be obtained prior to initial infusion to assess ARIA risk. During treatment, conduct an ARIA monitoring MRI before Infusions 2, 3, 4 and 7 and if symptoms consistent with ARIA occur.						
PROVIDER INFORMATION						
Physician Name:		Lic.#:		DEA #:		
Practice Name:				NPI#:		
Address:				City/State/Z	ip:	
Office Contact:		Phone:			Fax:	
Supervisory Physician (if applicable):						
PLEASE ATTACH						
☐ Patient demographics & front/back copy of all insurance cards (prescription & medical) ☐ Vaccine status (any vaccination) and documentation of any recent vaccinations						
□ Recent office visit notes, history & physical, lab & pertinent procedure results □ Letter of medical necessity if drug dosing or indication is outside of FDA guidelines						
☐ Current medication list & list of prior medications tried and failed (with dates)						
☐ Current medication is to is to prior medications tried and railed (with dates) ☐ Line access documentation/verification if applicable						
NURSING & LAB ORDERS						
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.  Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mLOR 10units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line						
Lab Orders:						
PRESCRIPTION ORDERS						
Anaphylaxis Kit:□ Epinephrine 0.3mg IM as needed□ Solu-cortef 250mg-500mg IV as needed□ Solu-Medrol 60mg - 125mg IV as needed(Check all that apply)□ Diphenhydraminemg IV as needed□ NS Hydration 500 ml IV over 30 minutes as needed□ Other						
Creck all that apply   □ Diplictingual line						
(Check all that apply)						
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary						
PRODUCT	, ,		CRIPTION INFORM			REFILLS
Is this a first dose?  No If No, when was last dose given? When is patient due for next dose?						
						NONE
	□ Induction: 700mg IV infusion via □ gravityOR□ pump over 30 minutes every 4 weeks x 3 doses					NUNE
☐ KISUNLA	□ Maintenance: 1400mg IV infusion via □ gravity OR □ pump over 30 minutes every 4 weeks □ □					
	If missed dose, administer the same dose as soon as possible and continue every 4 weeks.					
	Obtain MRI prior to 2nd, 3rd, 4th, and 7	th infusions. MRI resu	Its must be performed and clea	red by MD to	proceed to next infusion.	
□ OTHER						NONE
By signing this fo	m and utilizing our services, you are author	izing Amerita to serve a	s your prior authorization design	nated agent in	dealing with medical and prescription insurance com	panies.

Prescriber's Signature
Dispense as Written

© 2024 Amerita Inc. All rights reserved.

AME EVI\_KISUNLA REFER 12.24

Print Name Date

Prescriber's Signature Substitution Permitted

Print Name

Date



